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The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly
increased accumulation of human genotypic, phenotypic and clinical data, and improved our
understanding of the spectrum of clinical manifestations. As a result, the WHO disease
classification of EVD underwent major revision.
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Former filovirus disease names
Filoviruses, the members of the family Filoviridae, are
currently classified into one proposed and five established genera (Supplementary Table 1). Of the twelve
described filoviruses, six have been identified as aetiological agents of naturally occurring human disease
outbreaks.
The International Classification of Diseases (ICD;
Supplementary Box 1) is primarily a statistical tabulation. Consequently, frequently observed diseases
with large patient cohorts are more likely to have their
own disease names, codes and subcategories of disease
manifestations than uncommonly occurring diseases
because larger cohorts ensure statistical reliability
of disease descriptions. Given the past low number of
filovirus disease outbreaks and overall case numbers
(34 disease outbreaks until 2 013, involving 2,872 cases
and 1,968 deaths), it is not surprising that the diseases
caused by filoviruses were not captured by early ICD
iterations. In ICD-9, the only code defining filovirus
diseases was ‘078.89 Other specified diseases due to
viruses’. Consequently, various unofficial filovirus disease names have been used in the scientific literature
(Supplementary Tables 2,3).
The currently used ICD-10 recognizes filovirus diseases specifically via entries ‘A98.4 Ebola virus disease
(EVD)’ and ‘A98.3 Marburg virus disease (MVD)’ since
1994. However, ICD-10 does not specify which filoviruses are considered to cause which of the two diseases,
offer disease definitions or account for unusual disease
manifestations (for example, subclinical or persistent
infections).
A need for new filovirus disease names
In 2014, Ebola virus (EBOV) was identified as the aetiological agent of an EVD outbreak in Western Africa that,
from 2013 to 2016, caused at least 28,652 human infections and 11,325 deaths. This single outbreak involved
almost ten times the combined number of patients from
all previous filovirus disease outbreaks. Consequently,
the clinical presentation of EVD could be refined using
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statistical measures, and subclinical EBOV infections
leading to sexual transmission or disease relapse were
substantiated through clinical observations. In addition, often-debilitating sequelae in EVD survivors were
observed longitudinally for the first time using large
cohorts. As clinical research data on EVD accumulated,
the coverage of filovirus disease in ICD-10 was inadequate to cover complex clinical presentations of filovirus
disease.

Discussion framework
Expert panel and method. Responding to the WHO’s
public call for input in the development of ICD-11,
we assembled a large group of experts (the authors)
who treated filovirus-infected patients or were heavily involved in organizing the treatment of patients to
develop ICD-11’s entries on filovirus disease. Consensus
was obtained by step-wise, simple-majority, semi-blind
voting. The participants represented a wide spectrum
of scientists and health workers of both sexes and from
numerous countries, including African nations most
affected by human filovirus infections.
Main issues. ICD-10 recognizes two filoviruses diseases: EVD and MVD; however, four ebolaviruses
(members of the genus Ebolavirus) cause disease, with
EBOV only being one of them, and two marburgviruses (members of the genus Marburgvirus) cause
disease, with Marburg virus (MARV) being one of
them. The terms ‘Ebola virus disease’ and ‘Marburg
virus disease’ are therefore ambiguous: either ICD-10
does not capture diseases caused by ebolaviruses and
marburgviruses other than EBOV and MARV or EVD
and MVD are cover terms for diseases caused by all
ebolaviruses and marburgviruses (MARV and Ravn
virus (RAVV)), requiring authors to specify which
ebolavirus or marburgvirus caused a particular EVD
or MVD outbreak. These ambiguities cause major
confusion in communication among researchers and
copy editors who are not necessarily familiar with the
differences between ‘Ebola virus’ and ‘ebolavirus’ or
VOLUME 17 | MAY 2019 | 261
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Box 1 | New WHO-accepted filovirus disease classification
Main disease category: 1D60 Filovirus disease (FVD)
rFirst disease subcategory: 1D60.0 Ebola disease (EBOD)
- Second disease subcategories: 1D60.00 Bundibugyo virus disease (BVD)a; 1D60.01
Ebola virus disease (EVD)b; 1D60.02 Sudan virus disease (SVD)c; 1D60.03 Atypical
Ebola disease; 1D60.0Y Other specified Ebola diseased; 1D60.0Z Ebola disease, virus
unspecified
rFirst disease subcategory: 1D60.1 Marburg disease (MARD)
- Second disease subcategories: 1D60.10 Marburg virus disease (MVD)e; 1D60.11
Atypical Marburg disease; 1D60.1Y Other specified Marburg disease; 1D60.1Z
Marburg disease, virus unspecified
rFirst disease subcategory: 1D60.Y Other specified filovirus disease
rFirst disease subcategory: 1D60.Z Filovirus disease, virus unspecified
ICD-11, The International Classification of Diseases Revision 11. aCaused by Bundibugyo virus
(BDBV). bCaused by Ebola virus (EBOV). cCaused by Sudan virus (SUDV). dCaused by, for
instance, Taï Forest virus (TAFV). eCaused by Marburg virus (MARV) or Ravn virus (RAVV).

‘Ebola virus disease due to Ebola virus infection’
versus ‘Ebola virus disease due to Bundibugyo virus
infection’1. Consequently, the expert panel debated
whether the EVD and MVD entries in ICD-10 should
be merged into a single entry, whether the two terms
should be split into several entries based on aetiological agents or whether a hierarchical scheme should be
adopted to cover both possibilities.
Official virus taxonomy may change annually
through decisions made by the International Committee
on Taxonomy of Viruses (ICTV), but ICD updates and
revisions are released at much longer intervals. Hence,
the ICD cannot keep pace with taxonomic developments. Independence of ICD-11 filovirus disease names
from virus taxonomy considerations was therefore
thought to be imperative.

Results of expert panel discussions
A single umbrella term for the diseases caused by
filoviruses is urgently needed, as differentiation
between ICD-10’s EVD and MVD on clinical grounds
alone is impossible. Following the publication of the
‘WHO Best Practices for the Naming of New Human
Infectious Diseases’, this parent disease name should
not contain any geographical locations; people’s names;
species or class of animal or food; cultural, population, industry or occupational references; or components that incite undue fear2,3. Furthermore, the panel
almost unanimously discouraged the use of ‘haemorrhagic fever’ for any filovirus-associated disease name
because ‘haemorrhagic fever’ is not unambiguously
defined, and the majority of filovirus-infected individuals do not develop overt haemorrhage. Consequently,
health-care workers could misdiagnose filovirus diseases, or potentially infected individuals may not seek
admittance to a treatment unit based on the absence of
haemorrhage. After thorough consideration, ‘Filovirus
disease (FVD)’ was chosen as the ICD-11 parent disease term. Because filoviruses comprise a distinct and
monophyletic group of viruses, the expert panel felt
that the prefix ‘filo-’ was unlikely to disappear in the
near future if taxonomic changes to the virus family
would be required. Additional subcategories should be
established to codify diseases caused by filovirus that
262 | MAY 2019 | VOLUME 17

have not yet been associated with filovirus disease or
yet- to-be- discovered novel filoviruses, diseases very
likely caused by filoviruses without final agent confirmation, and filovirus diseases with ‘unusual’ clinical
presentations.
The panel advocated for two subcategories to the
filovirus parent entry for ebolavirus and marburgvirus
diseases and recommended, if necessary, further subcategorization. The classical distinction of ICD-10’s EVD
and MVD was felt to be important for traditional and
familiarity reasons. Furthermore, molecular evidence
is accumulating that ebolaviruses and marburgviruses
behave differently in vitro and in vivo, suggesting that
differences in clinical presentation of infections with
ebolaviruses or marburgviruses will become evident in
the future. ‘Ebola disease (EBOD)’ and ‘Marburg disease (MARD)’ were chosen for the major FVD subcategories (BOX 1): FVD due to ebolavirus and marburgvirus
infections, respectively. The WHO naming guidelines
were not applied in coining these terms because both
‘Ebola’ and ‘Marburg’ have been components of filovirus disease names since the 1970s and 1960s, respectively. The absence of the word ‘virus’ in the two disease
names makes them taxonomically independent and
therefore stable.
The panel then reintroduced the ICD-10 names
‘Ebola virus disease (EVD)’ and ‘Marburg virus disease
(MVD)’ as EBOD and MARD subcategories because of
their familiarity to the filovirus research community but
restricted the use of EVD and MVD to diseases caused
by agents belonging to only one species: EBOV (species
Zaire ebolavirus), and MARV and RAVV (both species
Marburg marburgvirus), respectively. Two additional
EBOD subcategory disease terms were added to cover the
remaining pathogenic filoviruses that have caused more
than one registered human infection: Bundibugyo virus
disease (BVD) and Sudan virus disease (SVD). Three
additional subcategories for both EBOD and MARD
were proposed: ‘Atypical Ebola/Marburg disease’ for
EBOD or MARD patients with unusual clinical presentations; ‘Other specified Ebola/Marburg disease’ for
EBOD or MARD patients infected with ebolaviruses or
marburgviruses not covered by BDV, EVD and SVD
or MVD (for example, disease due to Taï Forest virus
infection); and ‘Ebola/Marburg disease, virus unspecified’ for patients who are suspected to be infected with
an ebolavirus or marburgvirus in absence of virus
identification.
The expert panel did not establish a separate category
for filovirus-induced sequelae in filovirus disease survivors (for example, ‘post-Ebola syndrome’) as ICD-11
allows combinatorial coding (for example, ‘Atypical
Ebola disease’ plus ‘Arthritis’).

New official filovirus disease names
The panel submitted a proposal containing the proposed filovirus disease classification and nomenclature to the WHO’s ICD-11 Proposal Platform in April
2018. After peer review and appropriate revisions, the
new filovirus disease classification and nomenclature (BOX 1; Supplementary Table 4) were accepted in
May 2018 and subsequently incorporated into the
www.nature.com/nrmicro
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ICD-11 framework. The panel recommends that the
new filovirus disease names and abbreviations be used
immediately in forthcoming filovirus publications to
ensure a seamless transition once ICD-11 is adopted by
United Nations member states.
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